Interpace Biosciences, Inc. (OTCMKTS:IDXG) Stock Short Interest Climbs 550.0%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 13 shares, a growth of 550.0% from the October 15th total of 2 shares. Based on an average daily volume of 4,223 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Interpace Biosciences Trading Down 5.3%

Shares of OTCMKTS:IDXG traded down $0.35 during mid-day trading on Thursday, reaching $6.25. The stock had a trading volume of 502 shares, compared to its average volume of 1,812. The business’s 50 day moving average price is $6.57 and its 200 day moving average price is $8.04. Interpace Biosciences has a 1 year low of $4.95 and a 1 year high of $7.45. The company has a market cap of $34.64 million, a P/E ratio of 15.62 and a beta of 0.67.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings data on Monday, August 10th. The business services provider reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $9.13 million for the quarter. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%.

About Interpace Biosciences

Interpace Biosciences, Inc. is a molecular diagnostics company focused on improving the diagnosis and management of cancer and other complex diseases. The company develops and commercializes molecular tests that help physicians evaluate disease risk, guide treatment decisions and reduce uncertainty associated with conventional diagnostic procedures. Its portfolio has included tests for thyroid, pancreatic and gastroesophageal conditions. ThyGeNEXT and ThyraMIR are designed to help evaluate indeterminate thyroid nodules, while PancraGEN supports risk assessment for pancreatic cysts.